Rigel Pharmaceuticals, Inc. (RIGL)
Automate Your Wheel Strategy on RIGL
With Tiblio's Option Bot, you can configure your own wheel strategy including RIGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RIGL
- Rev/Share 14.9802
- Book/Share 4.5812
- PB 6.9022
- Debt/Equity 0.745
- CurrentRatio 2.0245
- ROIC 0.7218
- MktCap 567178691.0
- FreeCF/Share 3.6986
- PFCF 8.5741
- PE 5.7812
- Debt/Assets 0.2953
- DivYield 0
- ROE 4.3889
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'
Published: October 30, 2025 by: CNBC
Sentiment: Positive
Rigel Pharmaceuticals has landed on CNBC's list of top performing stocks of companies located in San Francisco.
Read More
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025.
Read More
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL)
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif. , Oct. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
Read More
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Read More
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Read More
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.
Read More
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.
Read More
What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Overlooked Stock: RIGL Nearly Doubles Stock in August
Published: August 15, 2025 by: Schwab Network
Sentiment: Positive
Rigel Pharmaceuticals (RIGL) is up 88% in August and more than tripled its stock price over the last year. The staggering upside rally began with a massive earnings beat and raised guidance.
Read More
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Best Momentum Stock to Buy for August 8th
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
RIGL, APG and CLSK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2025.
Read More
5 Best Stocks With Relative Price Strength to Buy Right Now
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
LendingTree, RIGL, and others are standing out with strong relative price strength amid market volatility.
Read More
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy?
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Rigel Pharmaceuticals, Inc. (RIGL) is looking like an interesting pick, as it just reached a key level of support. RIGL's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Read More
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Why Rigel (RIGL) Could Beat Earnings Estimates Again
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel (RIGL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 69.6% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress.
Read More
Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Earnings Estimates Rising for Rigel (RIGL): Will It Gain?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
About Rigel Pharmaceuticals, Inc. (RIGL)
- IPO Date 2000-11-29
- Website https://www.rigel.com
- Industry Biotechnology
- CEO Raul R. Rodriguez
- Employees 162